AZD6244 for Malignancies

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Malignancies+2 More
AZD6244 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will study the effects of a new drug called AZD6244 on patients with advanced cancer. They will be testing to see if the drug is safe and tolerable for patients.

Eligible Conditions
  • Malignancies
  • Tumors

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: assessed at each visit

assessed at each visit
To assess safety and tolerability of solid dose form of AZD6244
each visit
To assess the pharmacokinetics of the solid dose form of AZD6244

Trial Safety

Safety Progress

1 of 3

Side Effects for

Arm 1 - Erlotinib
50%Rash Acneiform
36%Diarrhea
32%Dry skin
32%Nausea
27%Anorexia
23%Increased blood bilirubin
23%Increased AST
23%Vomiting
14%Other skin and subcutaneous tissue disorders, specify
14%Oral mucositis
14%Weight loss
14%Epistaxis
14%Rash Maculopapular
9%Hyperglycemia
9%Increased alkaline phosphatase
9%Fatigue
5%Multi-organ failure
5%Dry mouth
5%Dyspnea
5%Hyponatremia
5%Pruritus
5%Lung infection
5%Palmar-plantar erythrodysesthesia syndrome
5%Hypoalbuminemia
5%Dysgeusia
This histogram enumerates side effects from a completed 2020 Phase 2 trial (NCT01248247) in the Arm 1 - Erlotinib ARM group. Side effects include: Rash Acneiform with 50%, Diarrhea with 36%, Dry skin with 32%, Nausea with 32%, Anorexia with 27%.

Trial Design

1 Treatment Group

AZD6244
1 of 1
Experimental Treatment

58 Total Participants · 1 Treatment Group

Primary Treatment: AZD6244 · No Placebo Group · Phase 1

AZD6244
Drug
Experimental Group · 1 Intervention: AZD6244 · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Selumetinib
FDA approved

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: assessed at each visit

Who is running the clinical trial?

AstraZenecaLead Sponsor
3,956 Previous Clinical Trials
91,808,803 Total Patients Enrolled
30 Trials studying Malignancies
4,429 Patients Enrolled for Malignancies
Emerging Oncology Medical Science Director, MDStudy DirectorAstraZeneca
4 Previous Clinical Trials
284 Total Patients Enrolled
1 Trials studying Malignancies
83 Patients Enrolled for Malignancies

Eligibility Criteria

Age 18+ · All Participants · 3 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 29th, 2021

Last Reviewed: October 15th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.